Nurix Therapeutics, Inc. NRIX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s accrued expenses?
- Nurix Therapeutics, Inc. (NRIX) reported accrued expenses of $25.87M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Nurix Therapeutics, Inc.'s accrued expenses increased by 30.0% year-over-year, from $19.89M to $25.87M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s accrued expenses?
- Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s accrued expenses has grown at a 17.8% compound annual growth rate (CAGR), from $13.16M to $21.54M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.